Trastuzumab rezetecan for injection | China Drugs List

Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.

Company
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Medicine type
Biologic
Therapeutic area
Oncology
Indications recorded in the public source
1. Monotherapy for adults with unresectable locally advanced or metastatic NSCLC with an activating HER2 (ERBB2) mutation who have received at least one systemic therapy. This indication has conditional approval; full approval depends on confirmatory study results. 2. Monotherapy for adults with locally advanced or metastatic HER2-positive breast cancer who have received at least one anti-HER2 treatment. 3. Monotherapy for adults with HER2-positive colorectal cancer after failure of oxaliplatin, fluorouracil and irinotecan.
Indication source and scope
Source date(s): 2026-08-04. Manufacturer prescribing information for Mainland China.
Prescribing-information limitations
Complete official prescribing information obtained. Mainland China label.
China availability status
Historical Chinese approval verified; current continuous market availability has not been checked for every product.
Overseas status
Market-by-market verification pending.
Insurance classification
Included in national insurance (Category B)
Insurance edition
2025 edition; effective 1 January 2026
Insurance restrictions
Limited to adults with unresectable locally advanced or metastatic NSCLC with an activating HER2 (ERBB2) mutation who have received at least one systemic therapy.
Insurance period
2026-01-01 to 2027-12-31
Insurance verification notes
Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.

Sources

Open the interactive record, public price references and discussions